Interstitial Lung Fibrosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Interstitial Lung Fibrosis – Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Lung Fibrosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Interstitial Lung Fibrosis
- The report reviews pipeline therapeutics for Interstitial Lung Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Interstitial Lung Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Interstitial Lung Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Interstitial Lung Fibrosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Interstitial Lung Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interstitial Lung Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3+2 Pharma LLC9 Meters Biopharma Inc
Accendatech Co Ltd
Accro Bioscience Suzhou Co Ltd
Acrobat Genomics Inc
AdAlta Ltd
Aeon Respire Inc
Afimmune Biopharma Ltd
Agency for Science
Technology and Research
AgomAb Therapeutics NV
Aileron Therapeutics Inc
Akeso Inc
AKSO Biopharmaceutical Inc
Alevin Therapeutics Ltd
Algernon Pharmaceuticals Inc
Altay Therapeutics Inc
Aluda Pharmaceuticals Inc
AlveoGene Ltd
Alveolus Bio Inc
Amakos Biotherapeutics Inc
Amgen Inc
AmMax Bio Inc
Amniotics AB
Amplia Therapeutics Ltd
AnaMar AB
Annji Pharmaceutical Co Ltd
Apaxen
APIE Therapeutics Inc
Aqua Therapeutics Co Ltd
Aqualung Therapeutics Corp
Aria Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Arroyo BioSciences LLC
AstraZeneca Plc
Atrapos Therapeutics LLC
Audax Therapeutics Ltd
AusBio Ltd
Austhera BioSciences Inc
Autotelic Bio Inc
Avalyn Pharma Inc
Aviceda Therapeutics Inc
Baylx Inc
Beijing Tide Pharmaceutical Co Ltd
BerGenBio ASA
Biolexis Therapeutics Inc
Bioven Group
Bioxytran Inc
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Bonac Corp
BreStem Therapeutics Inc
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
Calliditas Therapeutics AB
CarthroniX Inc
Ceapro Inc
Cedars-Sinai Medical Center
CellionBioMed Inc
CELLnLIFE Inc
Celon Pharma SA
Centre for Drug Design and Discovery
Centre National de la Recherche Scientifique
Certa Therapeutics Pty Ltd
Chemomab Therapeutics Ltd
Chengdu Huitai Biomedicine Co Ltd
Chengdu Zeling Biomedical Technology Co Ltd
Chiba University
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp.
Citryll BV
Collaborations Pharmaceuticals Inc
Createrna Science and Technology Co Ltd
CrystalGenomics Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
Curamys Co Ltd
Cynata Therapeutics Ltd
Cytonus Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
DICE Therapeutics Inc
DJS Antibodies Ltd
e-Therapeutics Plc
EffectorBio Inc
Elicio Therapeutics Inc
Elixiron Immunotherapeutics Inc
EmphyCorp Inc
Endeavor BioMedicines
Endogena Therapeutics Inc
Enzyvant Sciences Ltd
Epigen Biosciences Inc
Epirium Bio Inc
Epitracker Inc
ethris GmbH
Excalibur Pharmaceuticals Inc
Exorphia Co Ltd
Eyestem Research Pvt Ltd
F. Hoffmann-La Roche Ltd
Faknostics LLC
FibroBiologics Inc
FibroStatin SL
Foresee Pharmaceuticals Co Ltd
Galmed Pharmaceuticals Ltd
Gatehouse Bio
Genentech USA Inc
Genflow Biosciences Srl
Genome Protection Inc
Genosco Inc
Glycomantra Inc
GSNO Therapeutics Inc
Guangdong Raynovent Biotech Co Ltd
Guangzhou Henovcom Bioscience Co Ltd
Gubra ApS
H4Orphan Pharma
Hainan Haiyao Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
HEC Pharma Co Ltd
Heilongjiang ZBD Pharmaceutical Co Ltd
Hepion Pharmaceuticals Inc
Horizon Therapeutics Plc
Huabo Biopharm (Shanghai) Co Ltd
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
Humanetics Corp
HuniLife Biotechnology Inc
Imago Pharmaceuticals Inc
Immunomet Therapeutics Inc
inCerebro Co Ltd
Inhalis Therapeutics SA
Innovative Precision Medicine Group
Innovo Therapeutics Co Ltd
InSilico Medicine
Inventiva SA
Inversago Pharma Inc
iOnctura SA
Ionis Pharmaceuticals Inc
Isarna Therapeutics GmbH
Isterian Biotech Inc
Istesso Ltd
Iterion Therapeutics Inc
J2H Biotech
Jiangsu Hengrui Medicine Co Ltd
Joincare Pharmaceutical Group Industry Co Ltd
JW Pharmaceutical Corp
Kadmon Holdings Inc
KARE Biosciences Inc
Kinarus AG
Kintor Pharmaceutical Ltd
Kither Biotech Srl
Lamellar Biomedical Ltd
Lanier Biotherapeutics Inc
Lassen Therapeutics 1 Inc
LifeArc
Lignamed LLC
Liminal BioSciences Inc
Lispiro LLC
Lmito Therapeutics Co Ltd
Lotus Pharmaceutical Co Ltd
Mabwell Shanghai Bioscience Co Ltd
MannKind Corp
Max Biopharma Inc
Maxinovel Pharmaceuticals
MD Healthcare Inc
MDI Therapeutics Inc
Medical University of South Carolina
MediciNova Inc
Medispan
Melius Pharma AB
Metagone Biotech Inc
Metera Pharmaceuticals Inc
MetiMedi Pharmaceuticals Co Ltd
Mission Therapeutics Ltd
MitoImmune Therapeutics Inc
Molecure SA
MorphImmune
MyMD Pharmaceuticals Inc
Nankai University
National Institutes of Pharmaceutical R&D Co Ltd
National Jewish Health
National Taiwan University
NB Health Laboratory Co Ltd
New Amsterdam Sciences Inc
Nexel Co Ltd
Nextgen Bioscience
Nogra Pharma Ltd
Novartis AG
Novo Nordisk AS
NovoMedix LLC
Nuformix Plc
Oasis Pharmaceuticals LLC
Ocean Biomedical Inc.
Oleolive LLC
OliX Pharmaceuticals Inc
Omega Therapeutics Inc
Oncobix Co Ltd
Onegene Biotechnology Inc
Opsidio LLC
OptiKira LLC
OROX BioSciences Inc
Overseas Pharmaceuticals Ltd
Oxcia AB
Palo BioFarma SL
Panorama Research Institute
Pfizer Inc
Pharmaxis Ltd
Pieris Pharmaceuticals Inc
Pliant Therapeutics Inc
Prasan Pharmaceutical Consultants LLC
PRISM Pharma Co.
Ltd.
Pulmatrix Inc
Pulmongene Ltd
PulmoSIM Therapeutics
PureIMS BV
Puretech Health Plc
RDS2 Solutions Inc
Redx Pharma Plc
Regenasome Pty Ltd
Rejuvenation Technologies Inc
Remedy Cell Ltd
Reviva Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Ribomic Inc
Rohto Pharmaceutical Co Ltd
RS BioTherapeutics Inc
Rubedo Life Sciences Inc
Saje Pharma LLC
Saniona AB
Sanofi
Segue Therapeutics LLC
Senisca Ltd
Senolytic Therapeutics Inc
Shanghai Ark Biopharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Laifu Medical Technology Co Ltd
Shanghai Life Science & Technology
Shanghai Pharmaceuticals Holding Co Ltd
Shenzhen Tuwei Anchuang Technology Development Co Ltd
Shijiazhuang Sagacity New Drug Development Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Yiasuo Pharmaceutical Technology Co Ltd
SignalRx Pharmaceuticals Inc
Sino Biopharmaceutical Ltd
Sinovant Sciences HK Ltd
siRNAgen Therapeutics Corp
Sirnaomics Ltd
SiVEC Biotechnologies LLC
SK Chemicals Co Ltd
Spark Biopharma Inc
SpliSense Ltd
Structure Therapeutics Inc
Surrozen Inc
Suzhou Regend Therapeutics Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
SynDevRx Inc
Taiwan Liposome Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
TargetSite Therapeutics
Telomere Therapeutics
Tetragenetics Inc
Thirona Bio Inc
Thyron Pharmaceuticals Inc
Topadur Pharma AG
Trevi Therapeutics Inc
Tvardi Therapeutics Inc
Twinpigbiolab Co Ltd
UBE Corp
United Therapeutics Corp
University Hospital Freiburg
University of Strathclyde
VCANBIO Cell and Gene Engineering Corp Ltd
Vectus Biosystems Ltd
Velvio GmbH
Verona Pharma Plc
Vicore Pharma AB
Viridian Therapeutics Inc
Virtici LLC
VYNE Therapeutics Inc
Xfibra Inc
Yale University
Yungjin Pharm Co Ltd